This session will review the current approaches to managing salivary cancers and the systemic treatment for recurrent or metastatic salivary cancers.

This session will examine the current state of evidence surrounding de-escalation of treatment in patients HPV-associated oropharyngeal cancer.

David Burkett is employed by The Burkett Law Firm and has stock ownership in Abbvie and Eli Lily.

This session reviews head and neck cancer from a patient perspective.

This session entitled the “Development of Survivorship Programs” will present a practical approach to developing a Survivorship Program and embed survivorship strategies in the entire continuum of care for the head and neck cancer patient.  The session will be divided into three main areas:

This session will review the a growing clinical problem with staging, treatment and survival approaches of cutaneous squamous cell carcinoma.

This session will review ongoing advances in the management of thyroid cancers in the context of basic science discovery about their mutational makeup, evolving research on best practices and multidisciplinary treatment options, and advanced diagnostic and surgical techniques.

This session will review the latest science in the field of head and neck cancer.

The goal of this session is understand what is the current standard approach to treat HPV+ oropharyngeal cancer.  In this talk, the speaker discusses the various broad approaches to de-intensify treatment for this disease and give evidence why some of the approaches have not been successful.  The

This case-based panel discussion will provide a multidisciplinary approach to the management of early oral cavity cancer.  The session outline the current evidence related to intraoperative management of the margins for the primary tumor resection and also emerging techniques that may impact show

This session reviews head and neck cancers from a patient perspective.